⌕
iShares Industrials Bond ETF · ENGN · Nasdaq
Tenet 60 · Solid
Compare
$1.76−4.86%At closeTenet 60 · Solid
$1.76−0.09 (−4.86%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

iShares Industrials Bond ETF (ENGN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Seeking AlphaNov 16, 2026 · 13:22 ET
enGene Therapeutics Inc. (ENGN) Presents at UBS Global Biopharma Conference 2026 Transcript

enGene Therapeutics Inc. (ENGN) Presents at UBS Global Biopharma Conference 2026 Transcript…

● Seeking AlphaNov 11, 2026 · 22:28 ET
enGene Therapeutics Inc. (ENGN) Discusses Updated LEGEND Data and Regulatory Path for Detalimogene Transcript

enGene Therapeutics Inc. (ENGN) Discusses Updated LEGEND Data and Regulatory Path for Detalimogene Transcript…

● Business WireNov 11, 2026 · 16:03 ETEARNINGS EXPECTED BY DEC 21
enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated results from the pivotal Cohort 1 of …

● Business WireNov 11, 2026 · 16:01 ET
enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN) (“enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointments of Erik T. Goluboff, MD, MB…

● Business WireNov 6, 2026 · 08:00 ET
enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the follow…

● Defense WorldNov 6, 2026 · 02:29 ET
enGene Holdings Inc. (NASDAQ:ENGN) Stock Has Average Price Target of $11.05 According to Brokerages

enGene Holdings Inc. (NASDAQ: ENGN - Get Free Report) has earned an average recommendation of "Hold" from the fourteen research firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have r…

● MarketBeatOct 16, 2026 · 01:02 ET
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path

enGene NASDAQ: ENGN used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse, while community urolo…

● Seeking AlphaOct 15, 2026 · 14:24 ET
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript

enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript…

● Business WireOct 13, 2026 · 08:00 ET
enGene to Host KOL Webinar on October 15, 2026

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a webinar on Thursday, Octo…

● Seeking AlphaSep 14, 2026 · 10:41 ET
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● Seeking AlphaSep 10, 2026 · 15:50 ET
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market

enGene Therapeutics remains deeply undervalued, trading below its $3.97/share cash position despite pipeline and execution risks. ENGN's lead asset, detalimogene voraplasmid, faces FDA approval risk due to weak 12-month …

● Business WireSep 8, 2026 · 07:30 ETEARNINGS EXPECTED BY DEC 21
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter e…

● Business WireSep 1, 2026 · 08:30 ET
enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the follow…

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Dec 21. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

ANT13−7.0%
AAPL8+0.3%
FOX6−2.9%
META6−2.2%

Article counts from the last market-wide feed page, across every symbol we track and not just ENGN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.